KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Cash Flow (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Net Cash Flow for 18 consecutive years, with -$198.7 million as the latest value for Q1 2026.

  • For Q1 2026, Net Cash Flow fell 1008.2% year-over-year to -$198.7 million; the TTM value through Mar 2026 reached -$91.1 million, down 7.52%, while the annual FY2025 figure was $129.5 million, 182.52% up from the prior year.
  • Net Cash Flow hit -$198.7 million in Q1 2026 for Ionis Pharmaceuticals, down from $34.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $115.7 million in Q2 2023 and bottomed at -$326.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$40.9 million, with a median of -$20.2 million recorded in 2022.
  • Year-over-year, Net Cash Flow tumbled 2065.0% in 2022 and then soared 673.14% in 2023.
  • Ionis Pharmaceuticals' Net Cash Flow stood at -$39.1 million in 2022, then surged by 219.99% to $46.9 million in 2023, then tumbled by 296.35% to -$92.0 million in 2024, then soared by 136.9% to $34.0 million in 2025, then tumbled by 685.19% to -$198.7 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$198.7 million, $34.0 million, and $41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.